With this collaboration,
Respiree's patient monitoring solution will be made available for
healthcare professionals in APAC through a pilot
program using Roche's blood glucose
monitoring system. The goal is to simplify clinical
workflows and augment diagnostic and monitoring capabilities,
leading to improved patient outcomes.
SINGAPORE, Sept. 17,
2024 /CNW/ -- Existing patient monitoring workflows
often rely on nurses managing patients from centralized
workstations, monitoring vitals and biomarkers at different
intervals, and manually collecting vitals. This process can be
inefficient, especially with limited workstations, multiple
workflows, increased patient volumes, and nursing shortages.
By the first quarter of 2025, Respiree will team up with Roche
to launch pilot programs across APAC that offer a simplified
approach to patient monitoring by combining Roche's cobas® pulse
system with Respiree's vital sign monitoring. The solution is also
expected in future to integrate machine learning models that
predict clinical deterioration using historical data with risk
scores at the bedside.
The cobas® pulse system, a point of care device, equipped with
digital health applications based on the Android operating system
allows for real-time administration and visualization, eliminating
the need for centralized workstations. Respiree's solution measures
multiple biometrics, including pulse rate, oxygen saturation,
respiratory rate, temperature, tidal depth,
inhalation-to-exhalation ratios, and has the capability to input
blood pressure measurements.
With the use of Respiree and cobas® pulse solutions, healthcare
professionals can register patients to Respiree's connected devices
in real-time, monitor historical data and potential deterioration
directly at the patient's bedside without needing to return to
workstations or medical carts, as well as simultaneously measure
vital signs and blood sugar. They can annotate clinical notes on
the Respiree solution in the cobas® pulse system.
"The use of Respiree with the cobas® pulse system has tremendous
potential to enhance clinical workflows. Nurses can administer
devices and view historical vitals in real-time without the need
for centralized workstations, providing immediate bedside insights
into patient progress. Additionally, nurses can automate the
extraction and measurement of vitals from connected devices almost
instantaneously, removing the need for manual scanning and
measurements," says Dr. Gurpreet
Singh, CEO and Founder of Respiree.
About Respiree
Respiree is an AI/ML health tech company building
clinically-validated AI for managing disease progression. Respiree
is CE marked and has received regulatory clearances from the
Therapeutic Goods Administration and the United States Food and
Drug Administration (FDA).
View original content to download
multimedia:https://www.prnewswire.com/news-releases/respiree-teams-up-with-roche-diagnostics-in-apac-to-introduce-a-new-simplified-way-of-hospital-patient-monitoring-302250237.html
SOURCE Respiree